Joshua A. Salomon

Professor of Global Health
Global Health and Population
Harvard School of Public Health
Professor
Home page:


Joshua Salomon, Ph.D. is a Professor of Global Health in the Department of Global Health and Population. His research focuses on priority-setting in global health, within three main substantive areas: (1) measurement of population health status and health valuations; (2) modeling and forecasting health outcomes and disease burden; and (3) evaluation of the potential impact and cost-effectiveness of current and future health interventions. A major emphasis has been on development of new approaches to data collection and analysis of health measurements with a particular focus on developing-country settings and aging populations. Another major research area revolves around development and application of analytic tools for priority-setting in global health. The goal of this work is to combine techniques of simulation modeling with decision analysis to inform decisions on use of existing health interventions and priorities for developing new technologies. Salomon earned his Ph.D. in 2001 from Harvard University.

Posted on January 28, 2013
Authors: Salomon J, Wang H, Freeman MK, Vos T, Flaxman AD, Lopez AD, Murray CJ
Lancet 2013 3802144-62  DOI: 10.1016/S0140-6736(12)61690-0

Healthy life expectancy (HALE) summarises mortality and non-fatal outcomes in a single measure of average population health. It has been used to compare health between countries, or to measure changes over time. These comparisons can inform policy... (more »)

Posted on March 4, 2013
Authors: Verguet S, Lim SS, Murray CJ, Gakidou E, Salomon J
J Infect Dis. 2013 207(1): 72-79  DOI: 10.1093/infdis/jis635

 

BACKGROUND:

Measuring the survival of human immunodeficiency virus-infected adult patients enrolled in antiretroviral therapy (ART) programs is complicated by short observation periods and loss to follow-up. We synthesized dat... (more »)

Posted on August 29, 2013
JAMA 2013 310(6)  DOI: doi: 10.1001/jama.2013.13805
Posted on March 6, 2012
Authors: Salomon J, Carvalho N, Gutiérrez-Delgado C, Orozco R, Mancuso A, Hogan DR, Lee D, Murakami Y, Sridharan L, Medina-Mora ME, González-Pier E
BMJ 2012  DOI: 10.1136/bmj.e355

OBJECTIVE:

To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.

DESIGN:

Cost effectiveness analysis based on epidemiological modelling.more »)

Posted on May 14, 2012
Authors: Salomon J, Carvalho N, Gutiérrez-Delgado C, Orozco R, Mancuso A, Hogan DR, Lee D, Murakami Y, Sridharan L, Medina-Mora ME, González-Pier E
BMJ 2012 344  PubmedID: 22389335   DOI: 10.1136/bmj.e355

OBJECTIVE:

To inform decision making regarding intervention strategies against non-communicable diseases in Mexico, in the context of health reform.

DESIGN:

Cost effectiveness analysis based on epidemiological modelling.... (more »)

Posted on October 14, 2012
Authors: Bao L, Salomon J, Brown T, Raftery AE, Hogan DR
Sex Transm Infect 2012

United Nations Programme on HIV/AIDS reports regularly on estimated levels and trends in HIV/AIDS epidemics, which are evaluated using an epidemiological model within the Estimation and Projection Package (EPP). The relatively simple four-paramete... (more »)

Posted on October 30, 2012
Authors: Verquet S, Lim SS, Murray CJ, Gakidou E, Salomon J
J Infect Dis 2012  PubmedID: 23100567

Measuring the survival of adult patients in antiretroviral therapy (ART) programs is complicated by short observation pe... (more »)

Posted on November 27, 2012
Authors: McBain R, Salhi C, Morris JE, Salomon J, Betancourt TS
Br J Psychiatry 2012

Treatment coverage for mental disorders ranges from less than 10% to more than 90% across low- and middle-income (LAMI) countries. Studies have yet to examine whether the capacity of mental health systems might be adversely affected by the burdens... (more »)

Posted on December 2, 2012
Authors: Menzies NA, Cohen T, Lin HH, Murray M, Salomon J
PLoS Med 2012 9(11)

The Xpert MTB/RIF test enables rapid detection of tuberculosis (TB) and rifampicin resistance. The World Health Organization recommends Xpert for initial diagnosis in individuals suspected of having multidrug-resistant TB (MDR-TB) or HIV-associate... (more »)

Posted on December 2, 2012
Sex Transm Infect 2012 88(Suppl 2)

We previously developed a flexible specification of the UNAIDS Estimation and Projection ... (more »)

Posted on January 28, 2013
Authors: Bärnighausen T, Kyle M, Salomon J, Waning B
Health Policy Planning 2012 27(6)  DOI: 10.1093/heapol/czr058

Despite extraordinary global progress in increasing coverage of antiretroviral treatment (ART), the majority of people needing ART currently are not receiving treatment. Both the number of people needing ART and the average ART price per patient-y... (more »)

Posted on February 4, 2013
Authors: Hogan DR, Salomon J, Canning D, Hammitt JK, Zaslavsky AM, Bärnighausen T
Sex Transm Infect 2012 88Suppl 2:i17-23  DOI: 10.1136/sextrans-2012-050636

OBJECTIVES:

Population-based HIV testing surveys have become central to deriving estimates of national HIV prevalence in sub-Saharan Africa. However, limited participation in these surveys can lead to selection bias. We control for selectio... (more »)

Posted on June 16, 2011
Authors: Pande AH, Ross-Degnan D, Zaslavsky AM, Salomon J
Am J Prev Med 2011 41(1): 1-8  PubmedID: 21665057

BACKGROUND:

The 2010 Patient Protection and Affordable Care Act (PPACA) has been controversial. The potential impact of national healthcare reform may be considered using a similar set of state-level reforms including exchanges and a m... (more »)

Posted on September 15, 2011
Authors: Barnighausen T, Kyle M, Salomon J, Waning B
Health Policy Plan. 2011  PubmedID: 21914713

Despite extraordinary global progress in increasing coverage of antiretroviral treatment (ART), the majority of people needing ART currently are not receiving treatment. Both the number of people needing ART and the average ART price per patien... (more »)

Posted on October 3, 2011
Authors: Salomon J, Patel A, Neal B, Glasziou P, Grobbee DE, Chalmers J, Clarke PM
Med Care. 2011 49(10): 962-70  PubmedID: 21918400

BACKGROUND:

Valid and comparable measures of health outcomes are needed for clinical trials, studies on quality of healthcare, and population health monitoring.

OBJECTIVE:

To examine comparability of patient-reported hea... (more »)

Instructor:
Joshua Salomon
Term:
Spring 1
Instructor:
Stephen Resch
Term:
Spring 2
This course features case studies in the application of health decision science to policymaking and program management at various levels of the health system. Both developed and developing country contexts will be covered. Topics include: [1] theoretical foundations of cost-effectiveness analysis (CEA); [2] controversies and limitations of CEA in practice; [3] design and implementation of tools and protocols for measurement and valuation of cost and benefit of health programs; [4] integration of evidence of economic value into strategic planning and resource allocation decisions, performance monitoring and program evaluation; [5] the role of evidence of economic value in the context of other stakeholder criteria and political motivations.

RDS 282 will not be offered for 2010-2011

Dynamic Modelling of New TB Diagnostic Strategies

Estimating the impact and cost effectiveness of the GeneXpert tuberculosis assay in low resource, high burden settings

Cost-Effectiveness, Affordability, and Uncertainty

Even countries eligible for GAVI support for new vaccines will have to consider financial sustainability in addition to cost effectiveness